Key facts
- It has raised $25.0M; the latest was PE Growth/Expansion in Aug 2025.
- Notable investors include Ampersand Capital Partners, Dendis Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for ALPCO
- ·The full record, as it builds
Funding rounds
No funding rounds for ALPCO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ALPCO
Manufacturer of immunoassay-based products intended to serve both the life science research and clinical diagnostic communities. The company develops and offers specialty immunoassay products such as In Vitro Diagnostics (IVDs) and Research Use Only (RUO), as well as services for the investigation, detection, diagnosis, and treatment of health-related disorders and diseases, thereby assisting clients in the advancement of research and improvement of patient outcomes.
- Sector
- Healthcare
- HQ
- Salem, NH, United States
- Founded
- 1991
- Employees
- 55
- Website
- alpco.com/
- Ownership
- Privately Held (backing)
ALPCO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ALPCO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ALPCO in its N-PORT filings yet. We sweep new filings monthly.